Partial remission of a newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP

International Journal of Laboratory Hematology

Volumn 29, Issue 6, 2007, Pages 469-473

  Feldmann, G ^a,b   Nattermann, J ^a   Gerhardt, T ^a   Nahle C P ^a   Spengler, U ^a   Woitas, R ^a  

^a UNIVERSITY OF BONN   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diffuse large B cell lymphoma; Hairy cell leukemia; Hemodialysis; Immunochemotherapy; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; AGED; ANAMNESIS; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; COMBINATION CHEMOTHERAPY; DIAGNOSTIC IMAGING; DRUG SAFETY; DRUG TOLERABILITY; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TUMOR BIOPSY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKEMIA, HAIRY CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOPLASMS, SECOND PRIMARY; PREDNISONE; REMISSION INDUCTION; RENAL DIALYSIS; VINCRISTINE;

EID: 35848930362     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00879.x     Document Type: Article

References (33)

1. Abbondanzo S.L. Sulak L.E. (1991) Ki-1-positive lymphoma developing 10 years after the diagnosis of hairy cell leukemia. Cancer 67, 3117 3122.
2. Adler S.S., Shetty J. Golomb H.M. (1979) Coexistence of leukemic reticuloendotheliosis and histiocytic lymphoma: a case report. Cancer 43, 1872 1880.
3. Armitage J.O. Weisenburger D.D. (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. Journal of Clinical Oncology 16, 2780 2795.
4. Armitage J.O., Dick F.R. Corder M.P. (1978) Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia. Cancer 41, 422 427.
5. Arnalich F., Camacho J., Jimenez C., Lahoz C. Patron M. (1987) Occurrence of immunoblastic B-cell lymphoma in hairy cell leukemia. Cancer 59, 1161 1164.
6. Bhargava R., Barbashina V., Filippa D.A. Teruya-Feldstein J. (2004) Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia. Leukemia and Lymphoma 45, 1043 1048.
7. Boesler B., Czock D., Keller F., Griesshammer M., Seufferlein T., Karges W. Rasche F.M. (2005) Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrology, Dialysis, Transplantation 20, 1187 1191.
8. Cartron G., Watier H., Golay J. Solal-Celigny P. (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104, 2635 2642.
9. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P. Gisselbrecht C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 346, 235 242.
10. Davis K.M., Spindel E., Franzini D.A., Kitchens C.S. Braylan R.C. (1985) Anaplastic neoplasm in a patient with hairy cell leukemia. Cancer 56, 2470 245.
11. Downing J.R., Grossi C.E., Smedberg C.T. Burrows P.D. (1986) Diffuse large cell lymphoma in a patient with hairy cell leukemia: immunoglobulin gene analysis reveals separate clonal origins. Blood 67, 739 744.
12. Foucar K. Rydell R.E. (1980) Richter's syndrome in chronic lymphocytic leukemia. Cancer 46, 118 134.
13. Franssila K.O. (1979) Coincidental hairy cell leukemia and large cell malignant lymphoma. Archives of Pathology and Laboratory Medicine 103, 437 439.
14. Friedline J.A., Crisan D. Chen J. (1998) Blastic transformation in a case of hairy cell leukemia. Molecular Diagnosis 3, 163 169.
15. Huang A.T., Silverstein L., Gonias S.L., Rundles R.W. Raab-Traub N. (1987) Transformation of hairy cell leukemia to EBV genome-containing aggressive B cell lymphoma. Leukemia 1, 369 372.
16. Jillella A.P., Dainer P.M., Kallab A.M. Ustun C. (2002) Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. American Journal of Hematology 71, 219 222.
17. Lenz G., Golf A., Rudiger T., Hiddemann W. Haferlach T. (2003) Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine. Blood 102, 3457 3458.
18. Lopera G.A., Alvarez O.A. Lee M. (1995) Large cell lymphoma of the colon presenting as a second malignancy in a patient with hairy cell leukemia. Journal of Clinical Gastroenterology 21, 259 260.
19. Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., Wolfe R.A., Jones E., Disney A.P., Briggs D., McCredie M. Boyle P. (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354, 93 99.
20. Marcus R. (2003) Current treatment options in aggressive lymphoma. Leukemia and Lymphoma 44 (Suppl. 4 S15 S27.
21. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D. Dallaire B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 16, 2825 2833.
22. Mounier N., Briere J., Gisselbrecht C., Emile J.F., Lederlin P., Sebban C., Berger F., Bosly A., Morel P., Tilly H., Bouabdallah R., Reyes F., Gaulard P. Coiffier B. (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101, 4279 4284.
23. Nazeer T., Burkart P., Dunn H., Jennings T.A. Wolf B. (1997) Blastic transformation of hairy cell leukemia. Archives of Pathology and Laboratory Medicine 121, 707 713.
24. Niesvizky R., Zhu A.X., Louie D. Michaeli J. (1999) Epstein-Barr virus-associated lymphoma after treatment of macroglobulinemia with cladribine. New England Journal of Medicine 341, 55.
25. Rasche F.M., Keller F. Czock D. (2005) Chemotherapy in patients with renal failure, dialysis and after transplantation. Deutsche Medizinische Wochenschrift 130, 2043 2046.
26. Sanchez M.L., Almeida J., Gonzalez D., Gonzalez M., Garcia-Marcos M.A., Balanzategui A., Lopez-Berges M.C., Nomdedeu J., Vallespi T., Barbon M., Martin A., de la Fuente P., Martin-Nunez G., Fernandez-Calvo J., Hernandez J.M., San Miguel J.F. Orfao A. (2003) Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood 102, 2994 3002.
27. Schmits R., Glass B., Trumper L. Pfreundschuh M. (2001) Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL. Annals of Hematology 80 (Suppl. 3 B77 B83.
28. Stewart D.J. Keating M.J. (1982) Second malignancies in hairy cell leukemia (leukemic reticuloendotheliosis). American Journal of Hematology 13, 167 169.
29. Sun T., Grupka N. Klein C. (2004) Transformation of hairy cell leukemia to high-grade lymphoma: a case report and review of the literature. Human Pathology 35, 1423 1426.
30. Tomita M., Aoki Y. Tanaka K. (2004) Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs. Clinical Pharmacokinetics 43, 515 527.
31. Vardiman J.W., Variakojis D. Golomb H.M. (1979) Hairy cell leukemia: an autopsy study. Cancer 43, 1339 1349.
32. Vieira C.A., Agarwal A., Book B.K., Sidner R.A., Bearden C.M., Gebel H.M., Roggero A.L., Fineberg N.S., Taber T., Kraus M.A. Pescovitz M.D. (2004) Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77, 542 548.
33. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V. Engert A. (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94, 2217 2224.